Summary of Study ST002293
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001307. The data can be accessed directly via it's Project DOI: 10.21228/M8S124 This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
Study ID | ST002293 |
Study Title | Metabolic impact of anticancer drugs Pd2Spermine and Cisplatin on the lipophilic metabolome of brain from cell-derived xenograft mouse model of Triple-Negative Breast Cancer (part 2) |
Study Type | NMR-based metabolomics |
Study Summary | Platinum (Pt(II)) drugs, e.g. cisplatin (cDDP), are some of the most used chemotherapeutic agents, yet tumor acquired resistance and high toxicity are still current drawbacks. Palladium (Pd(II))-complexes are alternatives due to similar metal coordination and promising cytotoxic properties. Metabolomics can measure the metabolic response of drug-exposed tissues, unveiling insight into drug mechanisms and new markers of drug efficacy/toxicity. The present 1H NMR metabolomics study aims to characterize the in vivo response of the impact of a Pd(II)-complex with polyamine spermine (Pd2Spm), compared to cDDP, on nonpolar metabolism of brain from cell-derived xenograft mouse model of Triple-Negative Breast Cancer. |
Institute | University of Aveiro |
Department | Department of Chemistry and CICECO-Aveiro Institute of Materials |
Laboratory | Metabolomics from Ana M. Gil |
Last Name | Carneiro |
First Name | Tatiana João |
Address | Campus Universitário de Santiago, Aveiro, Aveiro, 3810-193, Portugal |
tatiana.joao@ua.pt | |
Phone | +351 234 370 200 |
Submit Date | 2022-09-14 |
Num Groups | 3 |
Total Subjects | 21 |
Num Females | 21 |
Raw Data Available | Yes |
Raw Data File Type(s) | fid |
Analysis Type Detail | NMR |
Release Date | 2022-12-15 |
Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Factors:
Subject type: Mammal; Subject species: Mus musculus (Factor headings shown in green)
mb_sample_id | local_sample_id | Treatment_group |
---|---|---|
SA220308 | xeno_B_EL_A_24_1_2 | Cisplatin-treated |
SA220309 | xeno_B_EL_A_25b_1_2 | Cisplatin-treated |
SA220310 | xeno_B_EL_A_33b_1_2 | Cisplatin-treated |
SA220311 | xeno_B_EL_A_16b_1_2 | Cisplatin-treated |
SA220312 | xeno_B_EL_A_32b_1_2 | Cisplatin-treated |
SA220313 | xeno_B_EL_A_28b_1_2 | Cisplatin-treated |
SA220314 | xeno_B_EL_A_14_1_2 | Cisplatin-treated |
SA220315 | xeno_B_EL_A_7_1_2 | Cisplatin-treated |
SA220316 | xeno_B_EL_C_20_1_2 | Control |
SA220317 | xeno_B_EL_C_26_1_2 | Control |
SA220318 | xeno_B_EL_C_27_1_2 | Control |
SA220319 | xeno_B_EL_C_17_1_2 | Control |
SA220320 | xeno_B_EL_C_29_1_2 | Control |
SA220321 | xeno_B_EL_B_23b_1_2 | Pd2Spm-treated |
SA220322 | xeno_B_EL_B_30b_1_2 | Pd2Spm-treated |
SA220323 | xeno_B_EL_B_22c_1_2 | Pd2Spm-treated |
SA220324 | xeno_B_EL_B_10b_1_2 | Pd2Spm-treated |
SA220325 | xeno_B_EL_B_8b_1_2 | Pd2Spm-treated |
SA220326 | xeno_B_EL_B_13b_1_2 | Pd2Spm-treated |
SA220327 | xeno_B_EL_B_18b_1_2 | Pd2Spm-treated |
SA220328 | xeno_B_EL_B_19b_1_2 | Pd2Spm-treated |
Showing results 1 to 21 of 21 |